Johnson & Johnson agreed to acquire mental-illness drug developer Intra-Cellular Therapies for about $15 billion.

The Brooklyn Nets knew they needed someone to step up when Mikal Bridges was traded to the New York Knicks over the summer. While Cam Thomas was a likely candid ...

Tom Brady is learning on the fly. Brady is part owner of the Las Vegas Raiders, which is a lovely step for his post-playing career, but also makes his other job ...

Johnson & Johnson has entered an agreement to acquire all outstanding shares of Intra-Cellular Therapies, in a ...

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by ...

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to ...

A reported favorite in the Raiders GM search has surfaced and it's questionable whether it benefits them in a quest to beat ...

During the early December press conference announcing Matt Eberflu’s ouster, Chicago Bears CEO Kevin Warren made comments ...

The annual conference features presentations from more than 500 private and public companies. Follow here for live coverage.

The biopharma industry’s deal-a-palooza, better known as the J.P. Morgan Healthcare Conference, has kicked off in San ...

Intra-Cellular Therapies (ITCI) stock rose more than 35% premarket after Johnson & Johnson (JNJ) agreed to buy the biopharmaceutical company for $132 a share. Read more: ...